Stemcell United Limited Logo

Stemcell United Limited

SCU.AX

(1.0)
Stock Price

0,00 AUD

-37.45% ROA

-66.48% ROE

-1.17x PER

Market Cap.

3.854.190,00 AUD

41.12% DER

0% Yield

-19.91% NPM

Stemcell United Limited Stock Analysis

Stemcell United Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Stemcell United Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (41%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.1x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-66.48%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-37.45%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Stemcell United Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Stemcell United Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

Stemcell United Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Stemcell United Limited Revenue
Year Revenue Growth
1998 0
1999 0 0%
2000 12.718.000 100%
2001 9.619.298 -32.21%
2002 127.186.640 92.44%
2003 312.823.364 59.34%
2004 477.769.000 34.52%
2005 769.138.000 37.88%
2006 1.013.432.000 24.11%
2013 0 0%
2014 0 0%
2015 74.753 100%
2016 31.619 -136.42%
2017 290.680 89.12%
2018 1.561.429 81.38%
2019 730.356 -113.79%
2020 730.356 0%
2021 14.338.812 94.91%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Stemcell United Limited Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 2.050.000 100%
2006 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 392.914 100%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Stemcell United Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 2.347.000 100%
2001 2.184.331 -7.45%
2002 2.459.171 11.18%
2003 2.680.988 8.27%
2004 3.033.000 11.61%
2005 2.830.000 -7.17%
2006 4.664.000 39.32%
2013 0 0%
2014 347.737 100%
2015 578.506 39.89%
2016 898.758 35.63%
2017 1.094.618 17.89%
2018 1.257.753 12.97%
2019 963.696 -30.51%
2020 829.836 -16.13%
2021 3.132.106 73.51%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Stemcell United Limited EBITDA
Year EBITDA Growth
1998 -8.184
1999 -13.458 39.19%
2000 635.000 102.12%
2001 1.138.642 44.23%
2002 3.895.505 70.77%
2003 10.204.480 61.83%
2004 12.993.000 21.46%
2005 5.882.000 -120.89%
2006 28.277.000 79.2%
2013 0 0%
2014 75.170.131 100%
2015 -35.494.762 311.78%
2016 -3.517.129 -909.2%
2017 -3.250.941 -8.19%
2018 -674.937 -381.67%
2019 -1.329.579 49.24%
2020 -1.370.494 2.99%
2021 -2.494.803 45.07%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Stemcell United Limited Gross Profit
Year Gross Profit Growth
1998 0
1999 0 0%
2000 5.559.000 100%
2001 3.918.150 -41.88%
2002 7.488.577 47.68%
2003 9.136.597 18.04%
2004 24.970.000 63.41%
2005 24.421.000 -2.25%
2006 46.139.000 47.07%
2013 0 0%
2014 0 0%
2015 -12.005 100%
2016 5.651 312.44%
2017 65.909 91.43%
2018 114.646 42.51%
2019 137.030 16.34%
2020 66.147 -107.16%
2021 2.386.876 97.23%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Stemcell United Limited Net Profit
Year Net Profit Growth
1998 -4.092
1999 273.539 101.5%
2000 -97.000 382%
2001 256.077 137.88%
2002 1.083.427 76.36%
2003 2.329.531 53.49%
2004 -2.284.000 201.99%
2005 -14.062.000 83.76%
2006 -2.848.000 -393.75%
2013 0 0%
2014 75.041.240 100%
2015 -35.618.359 310.68%
2016 -3.631.079 -880.93%
2017 -3.353.398 -8.28%
2018 -3.537.974 5.22%
2019 -1.579.888 -123.94%
2020 -1.389.942 -13.67%
2021 -2.855.254 51.32%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Stemcell United Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 0
1999 5 100%
2000 0 0%
2001 1 0%
2002 2 100%
2003 4 50%
2004 -2 500%
2005 -8 87.5%
2006 -2 -700%
2013 0 0%
2014 1 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Stemcell United Limited Free Cashflow
Year Free Cashflow Growth
1998 -868.229
1999 -1.119.835 22.47%
2000 -177.000 -532.68%
2001 -105.980 -67.01%
2002 -11.781 -799.58%
2003 -26.116.327 99.95%
2004 -26.771.000 2.45%
2005 -33.645.000 20.43%
2006 -34.170.000 1.54%
2014 0 0%
2015 -2.751.224 100%
2016 0 0%
2017 -275.256 100%
2018 -888.264 69.01%
2019 -1.282.281 30.73%
2020 0 0%
2021 -3.534.301 100%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Stemcell United Limited Operating Cashflow
Year Operating Cashflow Growth
1998 0
1999 -1.119.835 100%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2014 0 0%
2015 -2.582.493 100%
2016 0 0%
2017 -137.628 100%
2018 -888.264 84.51%
2019 -1.282.281 30.73%
2020 0 0%
2021 -2.620.089 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Stemcell United Limited Capital Expenditure
Year Capital Expenditure Growth
1998 868.229
1999 0 0%
2000 177.000 100%
2001 105.980 -67.01%
2002 11.781 -799.58%
2003 26.116.327 99.95%
2004 26.771.000 2.45%
2005 33.645.000 20.43%
2006 34.170.000 1.54%
2014 0 0%
2015 168.731 100%
2016 0 0%
2017 137.628 100%
2018 0 0%
2019 0 0%
2020 0 0%
2021 914.212 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Stemcell United Limited Equity
Year Equity Growth
1998 5.626.879
1999 5.191.691 -8.38%
2000 11.290.000 54.02%
2001 11.552.633 2.27%
2002 12.636.060 8.57%
2003 17.947.961 29.6%
2004 21.479.000 16.44%
2005 9.285.000 -131.33%
2006 25.255.000 63.24%
2013 -76.251.378 133.12%
2014 149.845 50986.84%
2015 4.154.558 96.39%
2016 2.124.166 -95.59%
2017 1.200.673 -76.91%
2018 2.081.513 42.32%
2019 760.030 -173.87%
2020 6.476.830 88.27%
2021 4.872.220 -32.93%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Stemcell United Limited Assets
Year Assets Growth
1998 12.040.314
1999 13.106.887 8.14%
2000 17.661.000 25.79%
2001 17.638.946 -0.13%
2002 37.812.089 53.35%
2003 80.483.026 53.02%
2004 138.008.000 41.68%
2005 205.926.000 32.98%
2006 280.755.000 26.65%
2013 21.105 -1330177.19%
2014 3.580.672 99.41%
2015 4.881.107 26.64%
2016 2.632.855 -85.39%
2017 1.581.642 -66.46%
2018 2.431.454 34.95%
2019 1.012.573 -140.13%
2020 9.231.091 89.03%
2021 7.264.425 -27.07%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Stemcell United Limited Liabilities
Year Liabilities Growth
1998 6.413.435
1999 7.915.196 18.97%
2000 6.371.000 -24.24%
2001 6.086.313 -4.68%
2002 25.176.029 75.82%
2003 62.535.065 59.74%
2004 76.857.000 18.63%
2005 138.445.000 44.49%
2006 212.785.000 34.94%
2013 76.272.483 -178.98%
2014 3.430.827 -2123.15%
2015 726.549 -372.21%
2016 508.689 -42.83%
2017 380.969 -33.53%
2018 349.941 -8.87%
2019 252.543 -38.57%
2020 2.754.261 90.83%
2021 2.392.205 -15.13%

Stemcell United Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0
Price to Earning Ratio
-1.17x
Price To Sales Ratio
0.27x
POCF Ratio
-1.28
PFCF Ratio
-1.09
Price to Book Ratio
1.1
EV to Sales
0.31
EV Over EBITDA
-1.8
EV to Operating CashFlow
-1.71
EV to FreeCashFlow
-1.27
Earnings Yield
-0.85
FreeCashFlow Yield
-0.92
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.01
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.92
ROE
-0.66
Return On Assets
-0.37
Return On Capital Employed
-0.57
Net Income per EBT
1.02
EBT Per Ebit
1.02
Ebit per Revenue
-0.19
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0.22
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.17
Operating Profit Margin
-0.19
Pretax Profit Margin
-0.19
Net Profit Margin
-0.2

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0.35
Capex to Revenue
-0.06
Capex to Depreciation
-3.89
Return on Invested Capital
-0.63
Return on Tangible Assets
-0.37
Days Sales Outstanding
85.32
Days Payables Outstanding
0.27
Days of Inventory on Hand
40.34
Receivables Turnover
4.28
Payables Turnover
1351.88
Inventory Turnover
9.05
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0.41
Debt to Assets
0.16
Net Debt to EBITDA
-0.25
Current Ratio
2.11
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.41
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
1017207
Debt to Market Cap
0.32

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Stemcell United Limited Dividends
Year Dividends Growth
2004 0
2005 0 0%

Stemcell United Limited Profile

About Stemcell United Limited

Stemcell United Limited, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, Greater China, and Malaysia. Its products include Caulerpa Lentillifera, a sea grape extract; Dendrobium Officinale Kimura et Migo, an orchid; Resina, a Daemonorops Draco Blume extract; and Cannabis Sativa, an industrial hemp. The company was formerly known as On Q Group Limited and changed its name to Stemcell United Limited in September 2015. Stemcell United Limited was incorporated in 1984 and is headquartered in Sydney, Australia.

CEO
Mr. Huan Qing Gu
Employee
31
Address
126 Phillip Street
Sydney, 2000

Stemcell United Limited Executives & BODs

Stemcell United Limited Executives & BODs
# Name Age
1 Ms. Belinda Cleminson
Joint Company Sec.
70
2 Ms. Elizabeth Spooner
Joint Company Sec.
70
3 Mr. Matthew Leonard
Executive Director
70
4 Mr. Huan Qing Gu
Chief Executive Officer, MD & Director
70
5 Mr. Chow-Yee Koh
Chief Financial Officer & Director
70

Stemcell United Limited Competitors